Abstract: The present invention relates to novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
Type:
Grant
Filed:
August 1, 2003
Date of Patent:
September 9, 2008
Assignee:
AB Science
Inventors:
Marco Ciufolini, Camille Wermuth, Bruno Gielthen, Alain Moussy
Abstract: Novel compounds selected from 2-(3-aminoaryl) amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
Type:
Application
Filed:
July 31, 2003
Publication date:
October 27, 2005
Applicant:
AB Science
Inventors:
Marco Ciufolini, Camille Wermuth, Bruno Gielthen, Alain Moussy
Abstract: The present invention relates to novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
Type:
Application
Filed:
August 1, 2003
Publication date:
June 10, 2004
Applicant:
AB Science
Inventors:
Marco Ciufolini, Camille Georges Wermuth, Bruno Gielthen, Alain Moussy
© 2025 Justia
